|
業務類別
|
Biotechnology |
|
業務概覽
|
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I. |
| 公司地址
| 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601 |
| 電話號碼
| +1 201 696-9345 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.protalix.com |
| 員工數量
| 213 |
| Mr. Dror Bashan |
Director, President and Chief Executive Officer |
美元 374.11K |
30/04/2025 |
| Mr. Yaron Naos |
Senior Vice President, Operations |
美元 215.55K |
30/04/2025 |
| Mr. Gilad Mamlok |
Senior Vice President and Chief Financial Officer |
-- |
21/07/2025 |
|
|
| Mr. Dror Bashan |
Director, President and Chief Executive Officer |
30/04/2025 |
| Dr. Eliot Richard Forster, M.B.A.,PhD |
Chairman of the Board |
30/04/2025 |
| Ms. Gwen A. Melincoff |
Independent Director |
30/04/2025 |
| Dr. Shmuel Ben-Zvi, PhD |
Independent Director |
30/04/2025 |
| Dr. Pol F. Boudes,M.D. |
Independent Director |
30/04/2025 |
| Mr. Amos Bar Shalev |
Independent Director |
30/04/2025 |
| Dr. Aharon Schwartz,PhD |
Independent Director |
30/04/2025 |
| Mr. Christian Elze |
Director |
30/04/2025 |
|
|
|
|
